Clinical Trial Update: BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports on a Phase 1/2 trial evaluating the combination of BMS-247550 with cisplatin in patients with metastatic or recurrent head and neck cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• BMS-247550
• CISPLATIN (cisplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED